368 related articles for article (PubMed ID: 35219791)
1. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J
J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791
[TBL] [Abstract][Full Text] [Related]
2. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
Lu JC; Zhang PF; Huang XY; Guo XJ; Gao C; Zeng HY; Zheng YM; Wang SW; Cai JB; Sun QM; Shi YH; Zhou J; Ke AW; Shi GM; Fan J
J Hematol Oncol; 2021 Nov; 14(1):200. PubMed ID: 34838121
[TBL] [Abstract][Full Text] [Related]
3. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum to: "PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176].
Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Cai JB; Ke AW; Fan J
J Hepatol; 2023 Apr; 78(4):881-882. PubMed ID: 36564318
[No Abstract] [Full Text] [Related]
5. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
[TBL] [Abstract][Full Text] [Related]
6. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
Sun G; Liu H; Zhao J; Zhang J; Huang T; Sun G; Zhao S; Zhang Z; Cao H; Rong D; Kong X; Ji Q; Liu L; Wang X; Tang W; Xia Y
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600662
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
10. GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.
Rong D; Wang Y; Liu L; Cao H; Huang T; Liu H; Hao X; Sun G; Sun G; Zheng Z; Kang J; Xia Y; Chen Z; Tang W; Wang X
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787938
[TBL] [Abstract][Full Text] [Related]
11. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
[TBL] [Abstract][Full Text] [Related]
12. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.
Zhu M; Zhang P; Yu S; Tang C; Wang Y; Shen Z; Chen W; Liu T; Cui Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):14. PubMed ID: 34996504
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
Zhou C; Weng J; Liu C; Liu S; Hu Z; Xie X; Gao D; Zhou Q; Sun J; Xu R; Li H; Shen Y; Yi Y; Shi Y; Sheng X; Dong Q; Hung MC; Ren N
Gastroenterology; 2023 Jun; 164(7):1261-1278. PubMed ID: 36863689
[TBL] [Abstract][Full Text] [Related]
14. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.
Wang X; Zhou T; Chen X; Wang Y; Ding Y; Tu H; Gao S; Wang H; Tang X; Yang Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246476
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody.
Li Z; Li B; Peng D; Xing H; Wang G; Li P; Wang J; Ye G; Chen J
Int J Oncol; 2018 Jun; 52(6):2079-2092. PubMed ID: 29620156
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
[TBL] [Abstract][Full Text] [Related]
17. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
[TBL] [Abstract][Full Text] [Related]
18. Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.
Kong X; Zheng Z; Song G; Zhang Z; Liu H; Kang J; Sun G; Sun G; Huang T; Li X; Rong D; Wang K; Tang W; Xia Y
Front Immunol; 2022; 13():876048. PubMed ID: 35812439
[TBL] [Abstract][Full Text] [Related]
19. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
20. Bufalin suppresses hepatocellular carcinogenesis by targeting M2 macrophage-governed Wnt1/β-catenin signaling.
Zhang X; Lu X; Shi J; Li Y; Li Y; Tao R; Huang L; Tang Y; Zhu X; Li M; Gao Y; Feng H; Yu Z
Phytomedicine; 2024 Apr; 126():155395. PubMed ID: 38340578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
